C71T
CANCELLED SECTION 71
06/03/2026
Voltar para busca
Dado oficial do USPTO
AQIX
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
50
Atualização mais recente
31/03/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 42
Data de depósito
03/05/2013
Data de registro
28/01/2014
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
06/03/2026
Última transação
31/03/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
709
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
GB
Examinador
ALVAREZ, COURTNEY
Unidade examinadora
L80
Localização atual
GENERIC WEB UPDATE
Titulares e representantes
Titulares
Aqix Limited
Representantes
Tracy Deutmeyer Fredrikson & Byron, P.A.
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemicals for use in scientific analysis; chemicals for scientific purposesmaking pharmaceutical and veterinary preparationsbeing media for storing organstissue and cells; cellbacteria and virus growth media for use with cellbacterial and viral cultures in scientific research
Classe 5
Solutions for medical and clinical use in supporting human and animal cellstissue and organs; solutions for medical and clinical use and application in infusion therapyorgan transplant perfusion and cell or tissue bio-specimen collection and preservationsuch preservation being to preserve stem cells and their therapeutic applications; solutions for intravenous use for medicalsurgical and veterinary purposes; cultures for growing cellsbacteria and viruses for medical and clinical purposes; solutions for medical and clinical use for replacingsynthesizingdilutingrehydrating and expanding human and animal bloodintravascular and extravascular fluids; solutions for medical and clinical use for cellorgan and tissue preservation and the creation of a homeostasis to regulate the environment of cellsorgans and tissues; solutions for medical and clinical use for testing drugs on ex vivo perfused human and animal cellstissue and organs; cellbacteria and virus growth mediastorage media and transportation media for medical or clinical use for stem cell and DNA research and therapy; pharmaceutical transfer agents or components for pharmaceuticals in the form of solutions for medical use for application in infusion therapyorgan transplant perfusion and cell or tissue bio-specimen collection and preservation; tissue regenerative pharmaceutical preparations and solutions; stem cells for medical and veterinary purposes; clinical diagnostic preparations for medical or veterinary use; clinical medical reagents; medical diagnostic reagents for proteomicgenomic and metabolomic analysis of tissuescellsbacteria and viruses and testing the stability of homeostasis within organstissuescellsbacteria and viruses for medical use; * none of the aforesaid * being or * relating to ready-made pharmaceuticals * substancespreparationscompositions or solutions * and none of the aforesaid * being * for use in connection with the * detection or * treatment of herpes and related viral diseases *for use with tissue or organs infected by herpes or related viral diseases *
Classe 42
Laboratory services for analytical testing; laboratory services relating to the researching of pharmaceuticals and solutions for medical and surgical use and solutions for supporting human and animal cellstissue and organssolutions for use and application in infusion therapyorgan transplant perfusion and cell or tissue bio-specimen collection and preservationsolutions for storing human and animal organstissues and cellssolutions for replacingsynthesizingdilutingrehydrating and expanding human and animal bloodintravascular and extravascular fluidssolutions for testing drugs on human and animal cellstissue and organsmedia for stem cell and DNA research and therapy; scientific research; medical transplant research services; medical research; scientific analysis of human tissue and human serum for medical research; stem cell and DNA scientific and medical research services; chemical research and development services; chemicalmedical and scientific testing and analysis for medical research purposes; testing of pharmaceutical solutions for medical research purposes; quality control services for others; clinical medical and scientific research; conducting of clinical trials for others; design and development of new technology and products for other uses in medical and veterinary fields; Informationadvisory and consultancy services relating to all of the aforesaid * laboratory services for analytical testing and to scientific research *
Publicações
Histórico de despachos e eventos da marca no USPTO.
50 publicações encontradas
RNWL
INTERNATIONAL REGISTRATION RENEWED
12/10/2023
REM4
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
28/01/2023
NCP7
NOTICE OF PARTIAL CANCELLATION SEC. 7 SURRENDER EMAILED
05/02/2021
NA75
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
04/02/2021
C75A
REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.
04/02/2021
C7P.
CANCELLED SEC. 7 - PARTIAL
04/02/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
18/12/2020
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
25/11/2020
ES75
TEAS SECTION 71 & 15 RECEIVED
28/07/2020
ES7R
TEAS SECTION 7 REQUEST RECEIVED
28/07/2020
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
28/01/2019
INNA
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
13/04/2018
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
10/04/2018
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
10/08/2017
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
10/08/2017
LIME
LIMITATION FROM THE IB EXAMINED AND ENTERED
10/08/2017
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
16/06/2017
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
27/10/2016
INNA
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
12/03/2016
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
07/01/2016
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
07/05/2015
PLGL
ASSIGNED TO PARALEGAL
07/05/2015
LIME
LIMITATION FROM THE IB EXAMINED AND ENTERED
07/05/2015
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
01/05/2015
NREP
NEW REPRESENTATIVE AT IB RECEIVED
14/11/2014
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
04/07/2014
FICS
FINAL DISPOSITION NOTICE SENT TO IB
17/06/2014
FIMP
FINAL DISPOSITION PROCESSED
17/06/2014
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
28/04/2014
R.PR
REGISTERED-PRINCIPAL REGISTER
28/01/2014
NREP
NEW REPRESENTATIVE AT IB RECEIVED
13/12/2013
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/11/2013
PUBO
PUBLISHED FOR OPPOSITION
12/11/2013
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
23/10/2013
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
08/10/2013
ALIE
ASSIGNED TO LIE
07/10/2013
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
25/09/2013
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
24/09/2013
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
24/09/2013
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
24/09/2013
RFNT
REFUSAL PROCESSED BY IB
17/09/2013
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
27/08/2013
RFRR
REFUSAL PROCESSED BY MPU
27/08/2013
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
25/08/2013
CNRT
NON-FINAL ACTION WRITTEN
24/08/2013
DOCK
ASSIGNED TO EXAMINER
22/08/2013
MAFR
APPLICATION FILING RECEIPT MAILED
13/08/2013
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/08/2013
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
08/08/2013
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace AQIX ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.